EasyBlog

This is some blog description about this site

COPENHAGEN, SEPTEMBER 06, 2016 – AntibioTx has been invited to present recent positive results with ATx201 at the ‘2nd Inflammatory Skin Disease Summit’ symposium in New York the 16-20th November 2016. 

The ‘2nd Inflammatory Skin Disease Summit’ is a symposium that directly addresses and describes new developments and therapies for key inflammatory skin diseases, such as psoriasis, atopic dermatitis and an increasing number of other inflammatory conditions. 

The main purpose of the symposium is to update practicing dermatologist, MD-scientists and researchers in the field of treating skin diseases. The Symposium will feature internationally recognized researchers and will provide new research within skin infections and guidelines for future treatments improving clinical outcomes for the patients.

This press release contains forward-looking statements. Forward-looking statements are statements that are not historical facts and can be identified by words such as committed, will, steps, may, can, portfolio, planned, advancing, look forward, expected, or similar words. These forward-looking statements are based upon current expectations, estimates, believed potentials and can, therefore, involve risks and uncertainties. Many of these risks and uncertainties can be difficult to predict and could be out of the control of AntibioTx A/S. We may not actually achieve our intended plans, and you should not place undue reliance on these forward-looking statements.

Continue reading

COPENHAGEN, AUGUST 19, 2016 – Dr. Keith Bostian is a well-renowned figure within science of medicine and has extensive experience with biotechnology industry entrepreneurship and has had executive operating roles in companies financed by leading venture firms within biotechnology. 

Morten Sommer, CSO of AntibioTx commented: ”I’m looking very much forward to the collaboration with Dr. Keith Bostian and have strong confidence that Keith will further help to accelerate recent progress on our chemistry platform to develop new chemical entities for treatment of unmet medical needs”.

This press release contains forward-looking statements. Forward-looking statements are statements that are not historical facts and can be identified by words such as committed, will, steps, may, can, portfolio, planned, advancing, look forward, expected, or similar words. These forward-looking statements are based upon current expectations, estimates, believed potentials and can, therefore, involve risks and uncertainties. Many of these risks and uncertainties can be difficult to predict and could be out of the control of AntibioTx A/S. We may not actually achieve our intended plans, and you should not place undue reliance on these forward-looking statements.

Continue reading

COPENHAGEN, AUGUST 07, 2016 – Recent in vivo studies in mice documents the antibacterial properties of ATx201 and that they compare favorably to marketed products. The CSO of AntibioTx, Dr. Morten Sommer, said “ATx201 looks promising in numerous points such as treatment duration, de novo resistance and effectiveness against multi-drug resistant bacteria including MRSA. We strongly believe that ATx201 will be a valuable asset in treating microbiome related disorders”.

This press release contains forward-looking statements. Forward-looking statements are statements that are not historical facts and can be identified by words such as committed, will, steps, may, can, portfolio, planned, advancing, look forward, expected, or similar words. These forward-looking statements are based upon current expectations, estimates, believed potentials and can, therefore, involve risks and uncertainties. Many of these risks and uncertainties can be difficult to predict and could be out of the control of AntibioTx A/S. We may not actually achieve our intended plans, and you should not place undue reliance on these forward-looking statements.

Continue reading

COPENHAGEN, MAY 16, 2016 – AntibioTx and the Train2Target consortium, comprising leading academic groups and SME’s in the antimicrobial space, has been awarded a Horizon2020 grant to fund research and development. The grant will focus on antimicrobial resistance and in particular how to harness the challenges of the increasing problem with antibiotic resistance. Through the grant, AntibioTx will offer a PhD-position to a top-talented microbiologist who is passionate about the development of new antibacterial medicines.

This press release contains forward-looking statements. Forward-looking statements are statements that are not historical facts and can be identified by words such as committed, will, steps, may, can, portfolio, planned, advancing, look forward, expected, or similar words. These forward-looking statements are based upon current expectations, estimates, believed potentials and can, therefore, involve risks and uncertainties. Many of these risks and uncertainties can be difficult to predict and could be out of the control of AntibioTx A/S. We may not actually achieve our intended plans, and you should not place undue reliance on these forward-looking statements.

Continue reading

COPENHAGEN, APRIL 07, 2016 – AntibioTx welcomes the collaboration with Professor Mylonakis and foresees it as a very important step towards extracting the compound class potentials. 

Professor Mylonakis is an expert in molecular biology, biostatistics, microbial and pathogenesis, which he often combines with a pragmatic problem-solving approach such as developing methods and strategies against antimicrobial resistance.

Professor Mylonakis is currently chief of the Infectious Diseases Division and Dean’s Professor of Medicine at the Warren Alpert Medical School of Brown. He has published more than 200 peer-reviewed scientific articles edited five books and has been on the editorial board of 10 scientific and peer-reviewed journals. 
Mylonakis has received several awards for his research, counting awards from the American Society for Microbiology and the Infectious Disease Society of America.

This press release contains forward-looking statements. Forward-looking statements are statements that are not historical facts and can be identified by words such as committed, will, steps, may, can, portfolio, planned, advancing, look forward, expected, or similar words. These forward-looking statements are based upon current expectations, estimates, believed potentials and can, therefore, involve risks and uncertainties. Many of these risks and uncertainties can be difficult to predict and could be out of the control of AntibioTx A/S. We may not actually achieve our intended plans, and you should not place undue reliance on these forward-looking statements.

Continue reading

News